Danish firm behind weight-loss drug Wegovy raises profit forecast to £15.3bn

Novo Nordisk, which is now Europe's most valuable company, also reports strong sales of diabetes drug Ozempic

Strong sales of diabetes and weight loss drugs Ozempic and Wegovy have prompted the Danish pharmaceutical company Novo Nordisk to raise its 2024 profit forecast to up to 15.3bn, with supply shortages starting to ease.

Europe's most valuable company, whose stock market value exceeds the size of the Danish economy, has struggled to keep up with runaway demand for the two weight-loss jabs.